nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

25.07.2023 | short review

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

verfasst von: Dr. Dominik A. Barth, Prof. Martin Pichler, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Summary

Treatment options for nonmuscle invasive urothelial carcinoma of the bladder (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG) instillations are currently limited and often total resection of the bladder is the only therapeutic option for these patients. Thus, novel treatment options that are safe and effective are needed to avoid the substantial treatment morbidity, impact on the quality of life and the significant surgical risk associated with radical cystectomies. Besides intravesical cytotoxic therapies, immune checkpoint inhibitors, cytokines or cancer vaccines, different approaches of intravesical application of adenoviruses are being evaluated in BCG-unresponsive NMIBC. Recently, intravesical nonreplicating adenovirus vector-based gene therapy with nadofaragene firadenovec, which induces intravesical interferon expression, was approved for the treatment of BCG-unresponsive NMIBC by the US Food and Drug Administration after a recently published phase III trial. In this short review, different adenoviruses that are currently being investigated in BCG-unresponsive NMIBC are discussed and the therapeutic potential of nadofaragene firadenovec is highlighted.

Vorheriger Artikel How the long-term follow-up is organized in young adult survivors of childhood cancer

Nächster Artikel Lipid nanoparticles in the treatment of lung cancer—hype or hope?

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed

Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75–94.CrossRefPubMed

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–95.CrossRefPubMed

Ripoll J, Ramos M, Montaño J, Pons J, Ameijide A, Franch P. Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca cancer registry associated to survival. BMC Cancer. 2021;21(1):676.CrossRefPubMedPubMedCentral

Nykopp TK, Batista da Costa J, Mannas M, Black PC. Current clinical trials in non-muscle invasive bladder cancer. Curr Urol Rep. 2018;19(12):101.CrossRefPubMed

Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 world health organization grading classification systems in non-muscle-invasive bladder cancer: a European association of urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur Urol. 2017;72(5):801–13.CrossRefPubMed

Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol. 2013;189(3):834–9.CrossRefPubMed

Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A, et al. Oncological outcomes of sequential Intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3(4):293–303.CrossRefPubMedPubMedCentral

Kamat AM, Bellmunt J, Choueiri TK, Nam K, De Santis M, Dreicer R, et al. KEYNOTE-057: phase 2 study of pembrolizumab for patients (pts) with bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol. 2016;34(15):TPS4576.CrossRef

10.

Black PC, Catherine T, Lerner SP, McConkey DJ, Lucia MS, Woods M, et al. S1605: phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer. J Clin Oncol. 2018;36(6):TPS527.CrossRef

11.

Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, et al. Phase 1 trial of ALT-801, an interleukin-2/T cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011;17(24):7765–75.CrossRefPubMedPubMedCentral

12.

Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor—armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12(1):305–13.CrossRefPubMed

13.

Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2391–7.CrossRefPubMed

14.

Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36(10):440–7.CrossRefPubMed

15.

Papageorgiou A, Dinney CPN, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007;6(6):872–9.CrossRefPubMed

16.

Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, et al. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol. 2019;37(10):2041–9.CrossRefPubMed

17.

Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E, Finnbladder Group. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study—FinnBladder III long-term results. J Urol. 2002;168(3):981–5.CrossRefPubMed

18.

Shepherd AR, Shepherd E, Brook NR. Intravesical bacillus Calmette-Guérin with interferon-alpha versus intravesical bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev. 2017;3(3):CD12112.PubMed

19.

Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, et al. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther. 2001;8(10):788–95.CrossRefPubMed

20.

Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004;10(3):525–32.CrossRefPubMed

21.

Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CNP. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study. Cancer Gene Ther. 2014;21(3):91–4.CrossRefPubMedPubMedCentral

22.

Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 2002;8(4):1258–70.PubMed

23.

Zhang X, Dong L, Chapman E, Benedict WF. Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Ther. 2008;15(12):817–22.CrossRefPubMedPubMedCentral

24.

Dinney CPN, Fisher MB, Navai N, O’Donnell MA, Cutler D, Abraham A, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190(3):850–6.CrossRefPubMedPubMedCentral

25.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, et al. Intravesical rAd-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol. 2017;35(30):3410–6.CrossRefPubMedPubMedCentral

26.

U.S. Food and Drug Administration. FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer. 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-high-risk-non-muscle-invasive-bladder-cancer. Accessed 23 Mar 2023.

27.

Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107–17.CrossRefPubMed

Titel: Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer
verfasst von: Dr. Dominik A. Barth
Prof. Martin Pichler, MD
Publikationsdatum: 25.07.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00899-w

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Late complications after oncological therapy

New developments in radiation oncology for head and neck cancers

ASH highlights 2022—multiple myeloma

Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma

Nasopharyngeal carcinoma

Emerging molecular drugs for the treatment of gastroesophageal tumors